Quantification of the effects of thrombin activatable fibrinolysis inhibitor and α2-antiplasmin on fibrinolysis in normal human plasma

Vance G Nielsen, Truitt C. Ellis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Two major proteins that inhibit fibrinolysis include thrombin activatable fibrinolysis inhibitor (TAFI) and α2-antiplasmin. Our goal was to quantify the contribution of TAFI and α2-antiplasmin to antifibrinolytic defenses with thrombelastography. Plasma activated with tissue factor/kaolin was subjected to fibrinolysis with tissue-type plasminogen activator (100 U/ml). Prior to activation, TAFI activity was inhibited with either potato carboxypeptidase inhibitor (25 μg/ml) or an anti-TAFI antibody, and α2-antiplasmin activity was inhibited with an anti-α2-antiplasmin antibody. Data were collected for 30 min, with the time of onset and rate of fibrinolysis determined. Compared with uninhibited samples, TAFI inhibition significantly (P < 0.05) decreased the time of onset of fibrinolysis by 70% and increased the rate of lysis by 70%. There was no difference between potato carboxypeptidase inhibitor and anti-TAFI antibody inhibition. Inhibition of α2-antiplasmin resulted in a significantly (P < 0.05) decreased time of onset (85%) and increased the rate of lysis (557%) compared with uninhibited samples. Inhibition of α2-antiplasmin activity resulted in a significantly (P < 0.05) greater fibrinolytic response than TAFI inhibition. In conclusion, utilization of standard inhibitors and thrombelastography permitted quantification of the effects of TAFI and α2-antiplasmin on fibrinolysis in plasma. Future investigation of diseases involving hypofibrinolysis (e.g. left ventricular assist devices) could be conducted using this assay system.

Original languageEnglish (US)
Pages (from-to)29-33
Number of pages5
JournalBlood Coagulation and Fibrinolysis
Volume18
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Carboxypeptidase B2
Antifibrinolytic Agents
Fibrinolysis
Thrombelastography
Carboxypeptidases
Solanum tuberosum
Antibodies
Kaolin
Heart-Assist Devices
Thromboplastin
Tissue Plasminogen Activator

Keywords

  • α-antiplasmin
  • Fibrinolysis
  • Thrombelastography
  • Thrombin activatable fibrinolysis inhibitor
  • Tissue type plasminogen activator

ASJC Scopus subject areas

  • Hematology

Cite this

@article{bf6528c8c8294685875802eb37f28cf6,
title = "Quantification of the effects of thrombin activatable fibrinolysis inhibitor and α2-antiplasmin on fibrinolysis in normal human plasma",
abstract = "Two major proteins that inhibit fibrinolysis include thrombin activatable fibrinolysis inhibitor (TAFI) and α2-antiplasmin. Our goal was to quantify the contribution of TAFI and α2-antiplasmin to antifibrinolytic defenses with thrombelastography. Plasma activated with tissue factor/kaolin was subjected to fibrinolysis with tissue-type plasminogen activator (100 U/ml). Prior to activation, TAFI activity was inhibited with either potato carboxypeptidase inhibitor (25 μg/ml) or an anti-TAFI antibody, and α2-antiplasmin activity was inhibited with an anti-α2-antiplasmin antibody. Data were collected for 30 min, with the time of onset and rate of fibrinolysis determined. Compared with uninhibited samples, TAFI inhibition significantly (P < 0.05) decreased the time of onset of fibrinolysis by 70{\%} and increased the rate of lysis by 70{\%}. There was no difference between potato carboxypeptidase inhibitor and anti-TAFI antibody inhibition. Inhibition of α2-antiplasmin resulted in a significantly (P < 0.05) decreased time of onset (85{\%}) and increased the rate of lysis (557{\%}) compared with uninhibited samples. Inhibition of α2-antiplasmin activity resulted in a significantly (P < 0.05) greater fibrinolytic response than TAFI inhibition. In conclusion, utilization of standard inhibitors and thrombelastography permitted quantification of the effects of TAFI and α2-antiplasmin on fibrinolysis in plasma. Future investigation of diseases involving hypofibrinolysis (e.g. left ventricular assist devices) could be conducted using this assay system.",
keywords = "α-antiplasmin, Fibrinolysis, Thrombelastography, Thrombin activatable fibrinolysis inhibitor, Tissue type plasminogen activator",
author = "Nielsen, {Vance G} and Ellis, {Truitt C.}",
year = "2007",
month = "1",
doi = "10.1097/MBC.0b013e3280129afe",
language = "English (US)",
volume = "18",
pages = "29--33",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Quantification of the effects of thrombin activatable fibrinolysis inhibitor and α2-antiplasmin on fibrinolysis in normal human plasma

AU - Nielsen, Vance G

AU - Ellis, Truitt C.

PY - 2007/1

Y1 - 2007/1

N2 - Two major proteins that inhibit fibrinolysis include thrombin activatable fibrinolysis inhibitor (TAFI) and α2-antiplasmin. Our goal was to quantify the contribution of TAFI and α2-antiplasmin to antifibrinolytic defenses with thrombelastography. Plasma activated with tissue factor/kaolin was subjected to fibrinolysis with tissue-type plasminogen activator (100 U/ml). Prior to activation, TAFI activity was inhibited with either potato carboxypeptidase inhibitor (25 μg/ml) or an anti-TAFI antibody, and α2-antiplasmin activity was inhibited with an anti-α2-antiplasmin antibody. Data were collected for 30 min, with the time of onset and rate of fibrinolysis determined. Compared with uninhibited samples, TAFI inhibition significantly (P < 0.05) decreased the time of onset of fibrinolysis by 70% and increased the rate of lysis by 70%. There was no difference between potato carboxypeptidase inhibitor and anti-TAFI antibody inhibition. Inhibition of α2-antiplasmin resulted in a significantly (P < 0.05) decreased time of onset (85%) and increased the rate of lysis (557%) compared with uninhibited samples. Inhibition of α2-antiplasmin activity resulted in a significantly (P < 0.05) greater fibrinolytic response than TAFI inhibition. In conclusion, utilization of standard inhibitors and thrombelastography permitted quantification of the effects of TAFI and α2-antiplasmin on fibrinolysis in plasma. Future investigation of diseases involving hypofibrinolysis (e.g. left ventricular assist devices) could be conducted using this assay system.

AB - Two major proteins that inhibit fibrinolysis include thrombin activatable fibrinolysis inhibitor (TAFI) and α2-antiplasmin. Our goal was to quantify the contribution of TAFI and α2-antiplasmin to antifibrinolytic defenses with thrombelastography. Plasma activated with tissue factor/kaolin was subjected to fibrinolysis with tissue-type plasminogen activator (100 U/ml). Prior to activation, TAFI activity was inhibited with either potato carboxypeptidase inhibitor (25 μg/ml) or an anti-TAFI antibody, and α2-antiplasmin activity was inhibited with an anti-α2-antiplasmin antibody. Data were collected for 30 min, with the time of onset and rate of fibrinolysis determined. Compared with uninhibited samples, TAFI inhibition significantly (P < 0.05) decreased the time of onset of fibrinolysis by 70% and increased the rate of lysis by 70%. There was no difference between potato carboxypeptidase inhibitor and anti-TAFI antibody inhibition. Inhibition of α2-antiplasmin resulted in a significantly (P < 0.05) decreased time of onset (85%) and increased the rate of lysis (557%) compared with uninhibited samples. Inhibition of α2-antiplasmin activity resulted in a significantly (P < 0.05) greater fibrinolytic response than TAFI inhibition. In conclusion, utilization of standard inhibitors and thrombelastography permitted quantification of the effects of TAFI and α2-antiplasmin on fibrinolysis in plasma. Future investigation of diseases involving hypofibrinolysis (e.g. left ventricular assist devices) could be conducted using this assay system.

KW - α-antiplasmin

KW - Fibrinolysis

KW - Thrombelastography

KW - Thrombin activatable fibrinolysis inhibitor

KW - Tissue type plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=33845738884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845738884&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e3280129afe

DO - 10.1097/MBC.0b013e3280129afe

M3 - Article

C2 - 17179823

AN - SCOPUS:33845738884

VL - 18

SP - 29

EP - 33

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 1

ER -